Near infrared II excitation conjugated polymers-based phototheranostic nanoplatform for hyperthermia-enhanced
Yingying Chen1, Ying Sun2, Yuning Qiu3
1Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ferroptosis has the potential to induce immunogenic cell death (ICD) and remodel the immunosuppressive tumor microenvironment (TME). However, intracellular antioxidant glutathione (GSH) inhibits the efficacy of ferroptosis. Consequently, enhancing iron ion uptake while simultaneously depleting GSH presents a promising strategy to improve ferroptosis efficacy. Herein, we have developed phenylboronic acid-modified near infrared II photothermal therapy (NIR-II PTT) conjugated polymers DPP-CPDT-PBA (DCP), which co-load Fe2+ and GSH scavenger cisplatin (Pt), and encapsulate them within an amphiphilic DSPE-mPEG2000 to finally construct nanoplatform DCP@Pt@Fe. The formulated DCP@Pt@Fe exhibits outstanding NIR-II photothermal property and NIR-II imaging tracking capability. The thermo- and acidic TME-responsive release of Pt and Fe2+ synergistically induces ferroptosis in cancer cells through Pt-mediated GSH consumption by forming stable Pt-GSH complexes and Fe2+-driven reactive oxygen species (ROS) generation via NIR-II PTT-enhanced Fenton reactions. Notably, ferroptotic tumor cells exhibit high immunogenicity, reprogram tumor-associated macrophage polarization, promote dendritic cell maturation, mobilize T cell activation, and significantly reverse the immunosuppressive TME. Simultaneously, interferon-γ (IFN-γ) produced by tumor-infiltrating immune cells inhibits SLC7A11 expression in cancer cells, which contributes to the ferroptosis therapeutic efficacy. Consequently, our nanoplatform DCP@Pt@Fe effectively eradicates ovarian cancer via synergistic NIR-II-PTT/ferroptosis/immunotherapy, providing an exciting new avenue for therapeutic interventions.
Ferroptosis has the potential to induce immunogenic cell death (ICD) and remodel the immunosuppressive tumor microenvironment (TME). However, intracellular antioxidant glutathione (GSH) inhibits the efficacy of ferroptosis. Consequently, enhancing iron ion uptake while simultaneously depleting GSH presents a promising strategy to improve ferroptosis efficacy. Herein, we have developed phenylboronic acid-modified near infrared II photothermal therapy (NIR-II PTT) conjugated polymers DPP-CPDT-PBA (DCP), which co-load Fe2+ and GSH scavenger cisplatin (Pt), and encapsulate them within an amphiphilic DSPE-mPEG2000 to finally construct nanoplatform DCP@Pt@Fe. The formulated DCP@Pt@Fe exhibits outstanding NIR-II photothermal property and NIR-II imaging tracking capability. The thermo- and acidic TME-responsive release of Pt and Fe2+ synergistically induces ferroptosis in cancer cells through Pt-mediated GSH consumption by forming stable Pt-GSH complexes and Fe2+-driven reactive oxygen species (ROS) generation via NIR-II PTT-enhanced Fenton reactions. Notably, ferroptotic tumor cells exhibit high immunogenicity, reprogram tumor-associated macrophage polarization, promote dendritic cell maturation, mobilize T cell activation, and significantly reverse the immunosuppressive TME. Simultaneously, interferon-γ (IFN-γ) produced by tumor-infiltrating immune cells inhibits SLC7A11 expression in cancer cells, which contributes to the ferroptosis therapeutic efficacy. Consequently, our nanoplatform DCP@Pt@Fe effectively eradicates ovarian cancer via synergistic NIR-II-PTT/ferroptosis/immunotherapy, providing an exciting new avenue for therapeutic interventions.
More Related Videos
09:01Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
06:42Plasmonic Photothermal Cancer Therapy: Nanoparticle-embedded Tumor-tissue-mimicking Phantoms for Visualizing Photothermal Temperature Distribution
Published on: May 9, 2025
